yes there’s no doubt there will be other compounds on top of these two and it’s clear they can pick an outstanding candidate also with revenue streams from lic deals that can roll on...
only the company will not go to holders to agree on pulling in other compounds as there’s no point - investors are not scientists and should not be the arbiters of direction - that’s for the science board.
a dividend payment after revenues are secured is likely if the company is not acquired before that phase comes to pass
hopefully we will roll on for years as we have confounded and amazed the market on our agile capability and ability to qualify the right opportunity X2 with Paxalisib and Cantrixil - if we do this with a third drug it sets and confirms the direction for the future.
